Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis

MLA

Jennifer A Hughes, et al. “Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.” Clinical Infectious Diseases, vol. 75, Apr. 2022, pp. 1772–80. EBSCOhost, https://doi.org/10.1093/cid/ciac252.

APA

Jennifer A Hughes, Belén P Solans, Heather R Draper, H Simon Schaaf, Jana L Winckler, Louvina van der Laan, Kendra K Radtke, Barend Fourie, Lubbe Wiesner, Anneke C Hesseling, Radojka M Savic, & Anthony J Garcia-Prats. (2022). Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clinical Infectious Diseases, 75, 1772–1780. https://doi.org/10.1093/cid/ciac252

Chicago

Jennifer A Hughes, Belén P Solans, Heather R Draper, H Simon Schaaf, Jana L Winckler, Louvina van der Laan, Kendra K Radtke, et al. 2022. “Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.” Clinical Infectious Diseases 75 (April): 1772–80. doi:10.1093/cid/ciac252.